Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diquafosol tetrasodium following PRK
NCT01381731Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2005
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in corneal wound comparing Diquafosol tetrasodium with Placebo (2 arms). Primary endpoint: Healing time at 12 weeks. Started Apr 2005; status: terminated.
02
Drugs
diquafosol
03
Conditions
corneal wound
Beyond the preview
Go deeper on NCT01381731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381731.